Abstract
Automated insulin delivery (AID) systems, which consist of an insulin pump, a continuous glucose monitoring system and a software algorithm to automate insulin delivery based on real time glycaemic data, are rapidly evolving. AID is now strongly recommended as the insulin delivery method of choice for people with type 1 diabetes. This article reviews the features and current multinational availability of the Omnipod® 5 Automated Insulin Delivery System and summarizes the latest evidence in support of its efficacy, safety and optimal use. It also provides a series of clinical vignettes illustrating advanced issues related to the initiation and ongoing optimization of insulin therapy using the system, including how to personalize settings and optimize glycaemic outcomes in a variety of clinical circumstances.